
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded topical gel containing dapsone, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing dapsone are listed in gel and tablet forms.
Gel bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Dapsone is a sulfone antibacterial and anti-inflammatory medicine, taken by mouth or used as gel, that a pharmacy may compound when a prescriber orders it.
Dapsone is a sulfone. It blocks the folic acid pathway by competing with para-aminobenzoic acid (PABA) and inhibiting the enzyme dihydropteroate synthase; it kills or stops the growth of Mycobacterium leprae, the cause of leprosy. In inflammatory skin disease it dampens neutrophil activity, although its exact mechanism in dermatitis herpetiformis and in acne is not known. Manufactured products include dapsone tablets, indicated for dermatitis herpetiformis and all forms of leprosy except cases known to resist dapsone, and Aczone gel and generic dapsone gels, with Aczone indicated for acne in patients 9 years and older. StatPearls lists off-label uses, not FDA-approved indications, including blistering, vasculitic and neutrophilic skin diseases, malaria and Pneumocystis jirovecii pneumonia. A prescriber might order dapsone compounded in a strength or form that is not manufactured. Compounded preparations are not FDA-approved and require a prescription.
Dapsone labels carry no boxed warning, but deaths have been reported with oral dapsone from agranulocytosis, aplastic anemia and other blood disorders. Mild red blood cell breakdown and a rise in methemoglobin (hemoglobin that carries less oxygen) occur in almost everyone taking it by mouth, more so with G6PD deficiency; methemoglobinemia needing hospital care has been reported with the gel. Serious skin reactions and nerve damage with muscle weakness can occur. Do not use it if you are allergic to dapsone, and tell your prescriber about a sulfa allergy, anemia or liver disease (MedlinePlus). Rifampin lowers dapsone levels, trimethoprim raises them, and pyrimethamine raises the risk of blood problems. Gel used with benzoyl peroxide can briefly turn skin yellow or orange. The tablet label advises use in pregnancy only if clearly needed. Oral dapsone passes into milk in substantial amounts; LactMed says it can be used while breastfeeding with infant monitoring for hemolysis. Get help right away for slate-gray lips or nail beds, and call your prescriber about sore throat, fever, pale skin, unusual bruising, yellowing skin or a rash.
Dapsone competitively antagonizes PABA and inhibits dihydropteroate synthase, and is bactericidal and bacteriostatic against M. leprae. In neutrophilic dermatoses it inhibits the myeloperoxidase-peroxide-halide cytotoxic system, may interfere with leukotriene B4-mediated chemotaxis and decreases neutrophil adherence to IgA. Oral dapsone is rapidly and nearly completely absorbed, with peak levels in 4 to 8 hours and a volume of distribution of about 1.5 L/kg. Plasma half-life ranges from 10 to 50 hours (average 28 hours). It undergoes N-acetylation and N-hydroxylation; StatPearls names CYP2E1, CYP2C9 and CYP3A. About 85% is recovered in urine as water-soluble metabolites. Systemic exposure from Aczone gel is about 1% of that from an oral tablet. Labeled indications: dapsone tablets (ANDA) for dermatitis herpetiformis and leprosy; Aczone gel (NDA207154) for acne vulgaris. Dosing is per prescriber. Before starting, treat severe anemia; check complete blood counts frequently (the label cites an FDA advisory committee schedule of weekly for the first month, monthly for six months, then semi-annually), monitor hemoglobin and watch for methemoglobinemia, hemolysis (especially with G6PD or methemoglobin reductase deficiency), neuropathy and skin reactions. Dapsone is not a controlled substance.
Wash your hands. Apply the amount on your label to clean, dry skin and spread it in a thin layer. For a metered pump, your label states the number of presses. For a dosing syringe, push the plunger to the mark. Let the gel dry before covering with clothing. Wash your hands afterward and keep the site from touching other people until it has dried. Do not apply to broken skin unless told to.
A gel can have a nonaqueous or a water-based base, and USP <795> sets its default beyond-use date by water content, not by the word gel. A nonaqueous gel usually carries a beyond-use date of up to 180 days at room temperature or refrigerated. A water-based gel carries up to 35 days with a preservative, or 14 days refrigerated without one. Your label states which applies. Keep the container closed, away from heat and open flame if it contains alcohol, out of reach of children, and discard after the beyond-use date on your label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Apply topically to affected area(s)